10/08/2026 – AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million subscribed by a limited number of investors Download PDF Category: 2026By Alexis BERNARD10 August 2026 Author: Alexis BERNARD Post navigationPreviousPrevious post:AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programsNextNext post:AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026Related PostsRevenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026AB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026
